The homepage of the GSK USA website

Getting ahead of disease is one of the greatest, most inspiring challenges there is on the planet. By pursuing this purpose together, we have the scale and expertise to positively impact the health of 2.5 billion people by the end of the decade. In doing so, we will deliver stronger and more sustainable growth as a company where people can thrive.

Unfortunately, we cannot provide comprehensive information about our products here, in compliance with regulations. If you are a healthcare professional, you can access more product information on our GSKPro website.. In the US, if you are a patient and have questions about our medicines, please contact the GSK Response Center.

Ahead Together. At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.

Over the last two years we have played a key role to develop treatments and vaccines against COVID. Through a partnership with Vir Biotechnology we have developed, and contracted, with the US Government for approximately $1 billion for our monoclonal antibody, Sotrovimab, which demonstrated it can reduce hospitalization and risk of death by 79% in adults with mild-to …

January 10 2025 GSK’s Shingrix new prefilled syringe presentation accepted for review by US FDA . If approved, the new presentation will offer a convenient administration option to healthcare professionals.

Get in touch USA Pennsylvania Address: GSK 2929 Walnut Street Ste. 1700 Philadelphia, PA 19104. North Carolina Address: GSK 410 Blackwell St. Durham, NC 27701

We are leading the way in developing a broad portfolio and innovative pipeline of vaccines to make an impact for society. We deliver over two million vaccine doses per day to people living in over 160 countries.

Explore our career opportunities all over the world

Aug 2, 2021 · The MMR vaccine developed by GlaxoSmithKline (GSK) was first registered in Germany in 1997 and is currently licensed in more than 100 countries worldwide, including all European countries, Canada, Australia and New Zealand, with more than 400 million doses distributed to date.